Company intelligence / Profile preview

Argus Pharmaceuticals Ltd

Changsha, Hunan, Chinamcneilargusindia.com ↗

Ownership: Private
Development stage: Other

Overview

Argus Pharmaceuticals has multiple entities globally. The Chinese entity focuses on API development through fermentation. A related entity is conducting the ARGUS trial for EPX-100 (clemizole HCl) in Dravet syndrome, which is currently in Phase 3 clinical trials.

Therapeutic areas: Neurology
Modalities: Small moleculesFermentation-based APIs
Industry: Biotech

Partnerships

Harmony Biosciences

Beyond the preview

Go deeper on Argus Pharmaceuticals Ltd.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Argus Pharmaceuticals Ltd.

Explore the full profile